Navigation Links
Celldex Therapeutics Receives Fast-Track Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma
Date:1/7/2008

PHILLIPSBURG, N.J., Jan. 7 /PRNewswire/ -- Celldex Therapeutics announced today that the U.S. Food and Drug Administration (FDA) has granted Fast Track designation to Celldex's CDX-110 for the treatment of EGFRvIII expressing Glioblastoma Multiforme (GBM). GBM is the most common and aggressive form of primary brain cancer and carries a very poor prognosis with current therapy. CDX-110 is an immunotherapy that targets the tumor-specific growth promoter EGFRvIII that can be expressed by GBM.

In the ACTIVATE Phase 2a study, GBM patients treated with CDX-110 showed a median survival time of 30 months, more than a 100 percent increase in survival, versus the historical control's median of 14.5 months. The study has demonstrated a median time-to-progression of 13 months (p=0.0001) versus the historical control's median of 6.4 months. GBM that recurred after treatment with CDX-110 consistently lost EGFRvIII expression with its aggressive growth signal. An extension study, ACT II, which combines CDX-110 with chemotherapy in a similar patient population, has not yet reached median time-to-progression or survival. Preliminary progression free survival (PFS) and overall survival (OS) data in ACT II look very similar to the ACTIVATE experience, and the data suggest that chemotherapy and CDX-110 can be administered concurrently while still maintaining strong immune responses.

In September, Celldex randomized its first patient into ACT III, a definitive Phase 2/3 randomized study of CDX-110 with radiation and temozolomide in patients with newly-diagnosed GBM. The clinical trial is investigating the anticancer activity, impact on survival, and safety of the addition of CDX-110 vaccine to standard of care, versus standard of care alone. Celldex recently announced that CDX-110 has also been granted Orphan Drug Status by the FDA. Celldex Therapeutics announced a definitive merger agreement with AVANT Immunotherapeutics, Inc. (Nasdaq:

SOURCE Celldex Therapeutics, Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Celldex Therapeutics Announces Orphan Drug Designation for CDX-110, a Novel EGFRvIII Vaccine for Glioblastoma Multiforme
2. Vicus Therapeutics to Present at the 234th American Chemical Society National Meeting in Boston, MA
3. Allos Therapeutics Initiates Study of PDX in Patients with Cutaneous T-Cell Lymphoma
4. Amicus Therapeutics Announces Second Quarter 2007 Financial Results
5. TorreyPines Therapeutics Completes Patient Enrollment in Phase IIb Clinical Trial of Tezampanel for the Treatment of Acute Migraine Headache
6. CV Therapeutics Announces Eight Abstracts Accepted for Presentation at the European Society of Cardiology Congress 2007
7. Pharmacopeia Assists the World Health Organization in the Discovery of Novel Therapeutics for the Treatment of Malaria
8. Protalix BioTherapeutics Treats First Patient in Phase III Clinical Trial of prGCD
9. TorreyPines Therapeutics Initiates a Phase I Multiple Dose Clinical Trial of Tezampanel
10. TorreyPines Therapeutics Completes Phase I Multiple Dose Clinical Trial of NGX267, a Selective M1 Agonist for the Potential Treatment of Cognitive Impairment Associated with Schizophrenia
11. Cell Therapeutics, Inc. (CTI) Launches Phase III Study for Pixantrone in Relapsed Indolent Non-Hodgkins Lymphoma (NHL)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/21/2014)... 2014 The spinal column is one of the ... carried to and from the brain through the column control ... Injury or ailment here can be life altering, and leave ... control over their body. Though back injury and disease can ... are more options available to make things better than ever ...
(Date:8/21/2014)... , Aug. 21, 2014 /CNW/ - The Canadian Epilepsy Alliance ... comic series designed to educate children about the most common ... Medikidz Explain Epilepsy comic series tells a fictional ... navigating middle school while living with epilepsy. ... there is still so much misinformation and lack of awareness ...
(Date:8/21/2014)... , N.Y. and HAMBURG, Germany , ... announced it is collaborating with Deutsches Elektronen-Synchrotron ( DESY ... Germany , to speed up management and storage ... Big Data and Analytics architecture based on IBM ... per second of data at peak performance and help ...
Breaking Medicine Technology:Don't Live in Pain: Four Life Improving Benefits of Back Surgery 2Action Heroes Harness Powers to Educate Children About Epilepsy 2Action Heroes Harness Powers to Educate Children About Epilepsy 3DESY and IBM Develop Big Data Architecture for Science 2DESY and IBM Develop Big Data Architecture for Science 3
... ROCKVILLE, Md., Dec. 16, 2010 Novavax, Inc. (Nasdaq: ... clinical trial to evaluate a new vaccine candidate to prevent ... U.S. Food and Drug Administration (FDA) and is no longer ... had received a question from the FDA regarding chemistry, manufacturing ...
... Resources, one of the world,s leading research and ... that, owing to its superb efficacy, acceptable safety ... Ironwood/Forest/Almirall/Astellas,s linaclotide will emerge as the market leader ... In 2019, linaclotide will garner blockbuster sales of ...
Cached Medicine Technology:NOVAVAX Receives FDA Clearance to Launch Phase I RSV Vaccine Clinical Trial 2NOVAVAX Receives FDA Clearance to Launch Phase I RSV Vaccine Clinical Trial 3NOVAVAX Receives FDA Clearance to Launch Phase I RSV Vaccine Clinical Trial 4For Treatment of Irritable Bowel Syndrome, Linaclotide Will Emerge as the Market Leader and Will Achieve Blockbuster Status in 2019 2
(Date:8/22/2014)... 22, 2014 Natural Clear Vision , ... restore his own vision from legally blind to perfect 20/20 ... investigative review. , “There is a huge portion of ... everyday function, and most people just think that’s the way ... surgery that can be pretty risky at times,” reports Michaels. ...
(Date:8/22/2014)... deletion in advanced non-small cell lung cancer (NSCLC) ... in epidermal growth factor receptor (EGFR) tyrosine kinase ... BIM deletion independently predicts overall survival (OS) of ... activate the programmed cell death also known as ... been detected in 12.8% of the Asian population ...
(Date:8/22/2014)... Rheumatoid arthritis (RA), a complex autoimmune disease that ... patients to not only cope with pain, disability ... as disrupted work, family life and marital functioning. ... residual pain and disability is common. In addition, ... high cost or side effects. Because of this, ...
(Date:8/22/2014)... London, UK (PRWEB) August 22, 2014 ... more magnetic for some clinical applications due to ... of the emerging innovations in ultrasound, such as ... imaging, are expected to keep the market moving ... as increasing mobility can enhance not only the ...
(Date:8/22/2014)... Mueller Sports Medicine is excited to ... new product that provides non-drug instant relief for plantar ... you heal. The package includes 7 days of relief, ... – it is not kinesiology tape. It’s made in ... for Plantar Fasciitis is a breakthrough in the ...
Breaking Medicine News(10 mins):Health News:Natural Clear Vision: Review Exposes Kevin Richardson’s Program for Restoring Vision Naturally 2Health News:Deletion predicts survival in advanced non-small cell lung cancer 2Health News:Study shows cognitive-behavioral coping skills training has positive effects on rheumatoid arthritis 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 2Health News:Global Top Ultrasound Market Suppliers Assessed in New VPG Research Report Available at MarketPublishers.com 3Health News:Mueller Introduces FasciaDerm® PFTape™ System for Plantar Fasciitis 2
... New York City has discovered that chronic pain occurs as ... colleagues were studying chronic pain at the molecular and cellular ... and the neurons becomes excited and begin to send signals ... the stimulus is removed the nerves become dormant and there ...
... mantids – that is, the female praying mantid eats ... possibility that males may also have something to gain ... In a paper in the August issue of The ... male risk-taking behavior in a praying mantis by altering ...
... facial transplant patient was discharged for a week after undergoing ... , ,Li Guoxing, 30, who had not seen his wife ... Xijing Hospital returned home Friday for a week-long visit to ... part of his face is alive and Li has been ...
... most common medical condition, chronic widespread pain is ... associated with fatigue, depression and poor sleep.// ... cancer patients deveolping FM like symptoms after treatment ... studies have shown contradictory results. A new study ...
... tested HIV positive was tied to his bedpost at the Meerut ... April after committing a robbery. He tested HIV positive only last ... College, which proved to be hopelessly inadequate to deal with his ... ago when a blood test confirmed he was HIV positive. He ...
... Alma Garcia, 41, were well aware of the toll ... was suffering from high blood pressure, diabetes and thyroid ... ,When they scheduled their gastric bypass surgeries at ... 2006, they joined a growing number of severely overweight ...
Cached Medicine News:Health News:Insufficent Anti-inflammatoy Proteins Leads to Chronic Pain 2Health News:Weight-Loss Surgeries Changing Lives 2Health News:Weight-Loss Surgeries Changing Lives 3Health News:Weight-Loss Surgeries Changing Lives 4
PosiBlot 30-30 Pads...
... VacuGene XL Vacuum Blotting System ... gels up to 20 30 ... Efficient and reproducible transfers improve blotting ... in the unit. Precise vacuum control ...
... Pens-Using a proprietary and patented technology, ADI ... called Antigen-Antibody pens-TM, that will allow researchers ... in any form or shape or size. ... to see antigen being written on the ...
... Advantages of using the Antigen-Antibody Pens-Using ... designed and developed specialized fountain pens, called ... deliver or write/mark the blotting membranes in ... specially formulated antigen-bonded colored dyes helps to ...
Medicine Products: